Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody Syndrome
Eculizumab to Enable Renal Transplantation in Patients With History of Antiphospholipid Antibody Syndrome or Catastrophic Antiphospholipid Antibody Syndrome
Sponsor: Johns Hopkins University
Listed as NCT01029587, this PHASE2 trial focuses on Antiphospholipid Antibody Syndrome and End Stage Renal Disease and remains completed. Sponsored by Johns Hopkins University, it has been updated 12 times since 2009, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2019 — Nov 2020 [monthly]
Active Not Recruiting PHASE2
-
Aug 2018 — Sep 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE2
-
Apr 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Apr 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Nov 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Johns Hopkins University
For direct contact, visit the study record on ClinicalTrials.gov .